39 / 62
C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl
37
Neumol Pediatr 2016; 11 (1): 33 - 37
Transplante pulmonar en pacientes con fibrosis quística
CONCLUSIÓN
El TP es la opción en pacientes con FQ con falla
respiratoria terminal. El TP mejora su sobrevida y calidad de
vida. Un manejo multidisciplinario en el pre y post trasplante
que incluya rehabilitación, kinesioterapia, nutriólogo,
broncopulmonar, infectólogo son esenciales para el éxito del
trasplante. Medidas a nivel nacional deberían ser implementadas
para aumentar el pool de donantes y disminuir la mortalidad en
lista de espera.
El autor declara no presentar conflicto de intereses
REFERENCIAS
1.
Corris PA. Lung transplantation for Cystic Fibrosis and
Bronchiectasis. Semin Respir Crit Care Med 2013;34:297-
304
2.
Hirche TO, Knoop C, Hebestreit H, Hogardt M. Practical
Guidelines: Lung Transplantation in Patients with Cystic
Fibrosis. Pulm Med 2014, 621342
3.
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand
AI, Goldfarb SB et al The Registry of the International Society
for Heart and Lung Transplantation: Thirty-second Official
Adult Lung and Heart-Lung Transplantation Report—2015;
Focus Theme : Early Graft Failure. J Heart Lung Transplant
2015;34:1264-77
4.
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand
AI, Goldfarb SB et al The Registry of the International Society
for Heart and Lung Transplantation: Thirty-second Official
Adult Lung and Heart-Lung Transplantation Report—2014;
Focus Theme :Retransplantation, J Heart Lung Transplant
2014;33;1009-24
5.
Kerem E, Reisman J, Corey M, Canny GJ, Levison H.
Prediction of mortality in patients with cystic fibrosis. N Engl
J Med 1992; 326:1187–1191
6.
Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken
ML. Developing cystic fibrosis lung transplant referral criteria
using predictors of 2-year mortality. Am J Respir Crit Care
Med 2002;166 ( Pt 1):1550–1555
7.
Augarten A, Akons H, Aviram M, Bentur L, Blau H, Picard E
et al. Prediction of mortality and timing of referral for lung
transplantation in cystic fibrosis patients. Pediatr Transplant
2001;5:339-42.
8.
Corris P. Lung Transplantation for Cystic Fibrosis and
Bronchiectasis. Semin Respir Crit Care Med 2013;34:297–
304
9.
Weill D, Benden C, Corris P, Dark J, Davis R, Keshavjee
S et al. A consensus document for the selection of lung
transplant candidates: 2014. An update from the Pulmonary
Transplantation Council of the International Society for Heart
and Lung Transplantation. J Heart Lung Transplant 2015;
34:1-15
10. Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK,
Hutcheon MA et al. Survival of lung transplant patients with
cystic fibrosis harboring panresistant bacteria other than
Burkholderia cepacia, compared with patients harboring
sensitive bacteria. J Heart Lung Transplant 2007;26;834–
838
11. Kelly A, Moran A. Update on cystic fibrosis-related diabetes.
J Cyst Fibros 2013:12:318-31
12. Hertz MI. The Registry of the International Society for Heart
and Lung Transplantation—Introduction to the 2012 annual
reports: new leadership, same vision. J Heart Lung Transplant
2012;31:1045–1051
13. Shigemura N, Bhama J, Gries CJ, Kawamura T, Crespo M,
Johnson B et al. Lung transplantation in patients with prior
cardiothoracic surgical procedures. American J Transplant
2012;12:1249– 1255
14. Parada MT, Sepúlveda C; Trasplante Pulmonar: estado actual;
Rev Med Clin Condes 2015;26:367-375